Key result
Absence of in-treatment ECG LV hypertrophy by both Sokolow-Lyon voltage and Cornell product was associated with a 30% lower risk of sudden cardiac death (HR 0.70; 95% CI 0.54-0.92).
Why the study?
Does regression of ECG left ventricular hypertrophy during antihypertensive therapy reduce the risk of sudden cardiac death in patients with hypertension and LVH?
Cohort (n=9,193)
Does regression of ECG left ventricular hypertrophy during antihypertensive therapy reduce the risk of sudden cardiac death in patients with hypertension and LVH?
Effect estimate: HR 0.70 (95% CI 0.54-0.92)
Regression of ECG left ventricular hypertrophy during antihypertensive therapy is independently associated with a significantly reduced risk of sudden cardiac death.
No takes yet. Share an insight, caveat, or question.
May support serial ECG monitoring in treated hypertension; leaves open whether LVH regression causally reduces sudden cardiac death.
Wachtell et al. (2007) conducted a cohort in Essential hypertension and ECG left ventricular hypertrophy (n=9,193). Absence of in-treatment LV hypertrophy vs. Presence of in-treatment LV hypertrophy was evaluated on Sudden cardiac death (SCD) (HR 0.70, 95% CI 0.54-0.92). Absence of in-treatment ECG LV hypertrophy by both Sokolow-Lyon voltage and Cornell product was associated with a 30% lower risk of sudden cardiac death (HR 0.70; 95% CI 0.54-0.92).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: